InsiderSource

MPM BIOVENTURES 2018, L.P.

10% Owner · SEC CIK 1729505
Insider at AKTS Aktis Oncology, Inc. ITOS iTeos Therapeutics, Inc. TRDA Entrada Therapeutics, Inc. DYN Dyne Therapeutics, Inc.
Advertisement

Buy track record

How this insider's open-market purchases have performed
50%
of buys now in profit
1 up · 1 down
Avg return since buy−36.7%
Median return−36.7%
Best trade+0.8%
Worst trade−74.2%
Buys scored2 (+6 n/a)
Average return by holding period — separates good entry timing from riding one long winner
After 1 month −2.0% 50% won · 2 trades
After 3 months −41.7% 0% won · 2 trades
After 6 months −74.6% 0% won · 1 trade
After 12 months −14.1% 0% won · 1 trade
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Jan 12, 2026 AKTS $18 $20.03M +12% −17.7% −20.3% — — +0.8%
Nov 2, 2021 TRDA $20 $2M +2.3% +13.7% −63.0% −74.6% −14.1% −74.2%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 2 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$25.07M
8 trades
Open-market sells
$35.12M
75 trades
Net flow
−$10.05M
Net selling
Total filings
90
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
Advertisement
ITOS
iTeos Therapeutics, Inc.
Buy MPM BioVentures 2014, L.P. · 10% Owner · Open-market purchase · filed Jul 29, 2020 ΔOwn +4.5%

Mpm Bioventures 2014, L.p., ITOS's 10% owner, spent $1.71M of their own money on 89,955 shares at $19, growing their stake 5%.

+$1.71M
89,955 sh @ $19
ITOS
iTeos Therapeutics, Inc.
Buy MPM BioVentures 2014, L.P. · 10% Owner · Open-market purchase · filed Jul 29, 2020 ΔOwn +4.5%

Mpm Bioventures 2014, L.p., ITOS's 10% owner, spent $113.9K of their own money on 5,994 shares at $19, growing their stake 5%.

+$113.9K
5,994 sh @ $19
ITOS
iTeos Therapeutics, Inc.
Buy MPM BioVentures 2014, L.P. · 10% Owner · Open-market purchase · filed Jul 29, 2020 ΔOwn +4.5%

Mpm Bioventures 2014, L.p., ITOS's 10% owner, spent $58.8K of their own money on 3,096 shares at $19, growing their stake 5%.

+$58.8K
3,096 sh @ $19
ITOS
iTeos Therapeutics, Inc.
Buy MPM BioVentures 2014, L.P. · 10% Owner · Open-market purchase · filed Jul 29, 2020 ΔOwn +4.5%

Mpm Bioventures 2014, L.p., ITOS's 10% owner, spent $1.08M of their own money on 56,814 shares at $19, growing their stake 5%.

+$1.08M
56,814 sh @ $19
ITOS
iTeos Therapeutics, Inc.
Buy MPM BioVentures 2014, L.P. · 10% Owner · Open-market purchase · filed Jul 29, 2020 ΔOwn +4.5%

Mpm Bioventures 2014, L.p., ITOS's 10% owner, spent $57.4K of their own money on 3,020 shares at $19, growing their stake 5%.

+$57.4K
3,020 sh @ $19
ITOS
iTeos Therapeutics, Inc.
Buy MPM BioVentures 2014, L.P. · 10% Owner · Open-market purchase · filed Jul 29, 2020 ΔOwn +4.5%

Mpm Bioventures 2014, L.p., ITOS's 10% owner, spent $21.3K of their own money on 1,121 shares at $19, growing their stake 5%.

+$21.3K
1,121 sh @ $19

Frequently asked questions

How is MPM BIOVENTURES 2018, L.P.'s win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from MPM BIOVENTURES 2018, L.P.'s SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.